Choksi Laboratories CFO Resigns Effective May 18

Choksi Laboratories Limited has informed BSE Limited regarding the resignation of its Chief Financial Officer, Mr. Vyangesh Choksi. The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company's Corporate Secretary and Compliance Officer, Prakhar Dubey, filed the necessary details with the exchange.

Resignation Details

Mr. Vyangesh Choksi (DIN: 00154926) tendered his resignation from the position of Chief Financial Officer on May 5, 2026. The resignation was taken on record by the Board of Directors during its meeting held on May 18, 2026. Consequently, Mr. Choksi has been relieved from the responsibilities of the CFO role with effect from the close of business hours on May 18, 2026.

Reason for Resignation

In his resignation letter addressed to the Managing Director, Mr. Vyangesh Choksi stated that the decision to step down was due to his commitment to ongoing multiple new projects within the company. He confirmed that there were no other material reasons for the resignation and that his sign-offs and certifications were based on the records available during his tenure.

Continuation as Director

Despite stepping down from the financial role, Mr. Vyangesh Choksi will continue to serve as the Whole Time Director of Choksi Laboratories Limited. The company has assured that all necessary regulatory and corporate formalities will be completed regarding this change in key managerial personnel.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+8.18%	+5.05%	+3.98%	-25.05%	-5.22%	+1,027.37%

Choksi Laboratories has notified BSE Limited of its forthcoming Board of Directors meeting, filed in compliance with Regulation 29(1) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The meeting, designated as the 02/2026-27 board meeting, has been scheduled for Monday, May 25, 2026, at 02:30 P.M., to be held at the company's registered office located at Survey No. 9/1, Near Tulsiyana Industrial Park, Kumerdi, Indore, 453555 (M.P.).

Board Meeting Agenda

The board meeting has been convened to deliberate on key financial and administrative matters. The following items are on the agenda:

Agenda Item:	Details
Primary Business:	Consider and approve standalone audited financial results for Q4 and year ended March 31, 2026
Additional Business:	Any other item with permission of the Chairman and consent of majority of Directors present, including at least one independent Director

The company has also confirmed that the required disclosures will be submitted in both XBRL mode (using the excel template provided by the Exchange) and PDF mode within the prescribed time limit.

Trading Window Closure

In continuation of an earlier disclosure dated March 26, 2026, Choksi Laboratories has reiterated that the trading window for dealing in the securities of the company has been closed with effect from April 1, 2026, pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended.

The trading window will reopen 48 hours after the declaration of the audited financial results for the quarter and year ended March 31, 2026. This restriction applies to all designated persons, their immediate relatives, and all connected persons covered under the aforesaid code.

Regulatory Filing Details

The intimation was signed and submitted by Prakhar Dubey, Company Secretary and Compliance Officer, on May 16, 2026, and has been addressed to the Corporate Relationship Department of BSE Limited. The company has requested BSE to take the information on record and disseminate it on the BSE website.